Protalix BioTherapeutics developed Gaucher disease drug Elelyso, which it partnered on with Pfizer, but it may be the rare disease drug's unique plant cell-based manufacturing system that is making the small Israeli biotech potentially worth $1 billion.
With pharma interest in rare-disease drugs becoming quite common, Protalix BioTherapeutics, maker of a rare disease drug partnered with Pfizer ($PFE), said today that it has hired Citigroup to help review "a broad array of product partnering, technology sharing and other strategic alternatives" for the Israel-based biotech company.
Just weeks after winning U.S. approval for their new Gaucher drug taliglucerase alfa, the EMA's Committee for Medicinal Products for Human Use says Pfizer and Protalix BioTherapeutics should be shut out of the EU in order to honor Shire's exclusive status for its currently used Vpriv.
Pfizer followed GlaxoSmithKline and other pharma companies that journeyed into the rare disease arena, paying $60 million upfront to partner with Protalix and agreeing to pay out up to $55 million in milestones.
After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).
Protalix BioTherapeutics ( $PLX ) reported this morning that the FDA is putting off its deadline for a final decision on its drug for Gaucher's disease. The new deadline is May 1, and the news quickly
Manufacturing remediation chugs along at Genzyme , which anticipates some supply constraints of Gaucher-disease treatment Cerezyme before the supply outlook improves in February. Operating under a
Amid its latest run for FDA approval of its Gaucher disease drug tied into a collaboration with Pfizer ( $PFE ), Protalix BioTherapeutics ( $PLX ) has published details from its Phase III package that
The FDA has issued a complete response letter for Protalix's Gaucher's disease drug taliglucerase alfa. But the good news for Protalix is that the developer won't be required to conduct any
Israel's Protalix BioTherapeutics says it is blazing a scientific path that will lead to a new recombinant protein therapeutic for Gaucher's disease that can be delivered orally, eliminating the need